Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
- Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with DaltonTx’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS
Waltham, MA and London, UK – May 27th, 2026 – Bonito Biosciences (“Bonito”), a biotechnology company building the data foundation for programmable oligotherapeutic delivery, and”) DaltonTx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and experimental data, today announced a collaboration to advance next-generation precision delivery systems for Bonito’s oligotherapeutic medicines.
